If there is one important thing we can learn from our current circumstances, and I am referring specifically to the world of biotechnology companies and the difficulty in getting a drug to commercialisation.
Do not buy biotech shares if you are looking for a guaranteed return!!
The more than promising results from pre-clinical and animal studies we were shown had us in a bit of a frenzy, and then Leslie and Yuman made several comments that got us further excited and all of sudden we were planning what we would do with the thousands, even hundreds of thousands dollars when surely Big Pharma would knock on the door with a huge pay cheque.
Now that we are being slapped with a big dose of reality, and many of us have lowered our expectations, even to the stage where many investors would be happy to see a return of their original investment.
So what has happened that has led us down this path of disappointment and fear, personally my belief is that we as investors have got ahead of ourselves, when Leslie and Yuman have given little titbits of good news we have extrapolated this news and jumped several steps.
What they have told is not a lie, however they forgot to add the big BUT, which would include;
But, it is very early on in these trials;
But, we will not see these results consistently;
But, we are still not sure how this treatment does what it does;
But, do not get your hopes too high;
But, we are operating in an extremely competitive market.
If you read the disclaimer, that is quickly brushed over at the beginning of each investor presentation, you will see the reality which basically tells you not to take on anything you are about to hear or see and base a financial decision on it.
Having said all of the above, I still feel positive about Imugene’s future prospects, based on the potential of the IP and the talent that has been gathered together to conduct these trials.
I am confident that the shareprice will not fall much further as we have key data drops in the next 3-6 months.
This may be seen by many experienced investors as naivety, and I would accept that appraisal, however many experienced investors have lost money on similar potential multi baggers and they were not companies offering such a noble cause for those unfortunate enough to suffer from a debilitating disease.
DYOR opinion only
(20min delay)